Skip to content

REGISTRATION NOW OPEN: Arfinn Med Medical Cannabis Efficacy Portal for Licensed Medical Professionals

REGISTRATION NOW OPEN: Arfinn Med Medical Cannabis Efficacy Portal for Licensed Medical Professionals

Arfinn Med, the first clinician-based medical professional and patient efficacy portal for medical cannabis treatments, is now open for registrations from licensed medical professionals. The free collaborative portal allows medical professionals to register, share, research and communicate HIPAA-compliant benchmark data for medical cannabis treatments. As a free tool for physicians, Arfinn Med offers a new way to enhance treatment plans and practices in an emerging industry.  

Arfinn Med reports screen

The free portal includes four key components:

Reports – generate a report or submit your own patient findings on treatment effectiveness, daily dosage, delivery method and more, specific to patient demographics

Community – connect with a national network of peers and join specialized groups and forums for real-time discussion regarding best practices

Industry News – access news, trends and announcements impacting the medical marijuana industry and physicians’ practices

Resources – tap into assets, such as patient engagement tools that allow physicians to more closely communicate with and monitor treatment progress, and receive discounts for telemedicine software and other products to help your practice grow

Any licensed medical professional is invited to register for the portal for free, regardless of state location and medical marijuana legalization. Additional benefits of registration include: enhanced visibility of your practice through inclusion in our Participating Physicians Directory, and access to medical marijuana patient informational videos to display in your office or waiting room.

If you’re ready to join a nationwide network of licensed medical professionals to learn and share best practices and treatment efficacies for medical marijuana, join Arfinn Med for free today.

Stories you may be interested in

Norfolk research company plans clinical trials using medical marijuana

Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions. Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer.…
Read More →

Data Migration and Mapping Functions

Medical software does not have a good reputation for user experience and intuitive design. It can seem like a full-time job just learning how to use these software solutions.  In fact, according to a study from Stanford Medicine, 74% of doctors responded that their EMR increased the number of hours they work every day and…
Read More →

Survey of oncologists finds knowledge gap on medical marijuana

As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers. Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial…
Read More →

How Medical Marijuana Affects Men vs. Women

As expected, men and women differ in a multitude of ways, from genetic makeup and hormonal behavior to how we process information and emotionally respond. The differences in our makeup are the exact reason why any medical treatment, including medical marijuana, will have a diverse impact on men vs. women. Let’s take a closer look…
Read More →

Medical Cannabis and Breast Cancer

October is breast cancer awareness month and we at Arfinn Med would like to reiterate the importance of early screening and regular tests.  According to the American Cancer Society: “Breast cancer is the most common cancer in American women, except for skin cancers. Currently, the average risk of a woman in the United States developing breast…
Read More →

Study on cannabis chemical as a treatment for pancreatic cancer may have ‘major impact,’ Harvard researcher says

Pancreatic cancer makes up just 3 percent of all cancers in America. But with a one-year survival rate of just 20 percent (and five-year survival rate of less than 8), it’s predicted to be the second leading cause of cancer-related death by 2020. Headlines about the illness, as a result, tend to be discouraging. But this month scientists from Harvard University’s Dana-Farber…
Read More →